From eaaae598ec23610193fff4656492d206bfd62ebc Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Tue, 28 Apr 2026 04:20:59 +0000 Subject: [PATCH] vida: extract claims from 2026-04-28-llm-vs-human-glp1-coaching-commoditization-limits - Source: inbox/queue/2026-04-28-llm-vs-human-glp1-coaching-commoditization-limits.md - Domain: health - Claims: 0, Entities: 0 - Enrichments: 4 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida --- ...p1-long-term-persistence-ceiling-14-percent-year-two.md | 7 +++++++ ...28-llm-vs-human-glp1-coaching-commoditization-limits.md | 5 ++++- 2 files changed, 11 insertions(+), 1 deletion(-) rename inbox/{queue => archive/health}/2026-04-28-llm-vs-human-glp1-coaching-commoditization-limits.md (98%) diff --git a/domains/health/glp1-long-term-persistence-ceiling-14-percent-year-two.md b/domains/health/glp1-long-term-persistence-ceiling-14-percent-year-two.md index b9af64f17..303ffe3f0 100644 --- a/domains/health/glp1-long-term-persistence-ceiling-14-percent-year-two.md +++ b/domains/health/glp1-long-term-persistence-ceiling-14-percent-year-two.md @@ -58,3 +58,10 @@ Truveta data shows the first 4 weeks (titration phase) are the highest-risk peri **Source:** on/healthcare.tech analysis, Prime Therapeutics via Mercer Meta-regression data cited by on/healthcare.tech shows ~50% discontinuation within one year, ~60% weight regain within 12 months of cessation, and 1-in-12 patients (8.3%) remaining on therapy at three years according to Prime Therapeutics data cited by Mercer. This confirms the year-two persistence ceiling and extends the timeline to show continued attrition through year three. + + +## Extending Evidence + +**Source:** Nicholas Thompson LinkedIn 2026; cross-reference to digital-behavioral-support-improves-glp1-persistence-20-percentage-points + +The $1.8B, 2-person AI-staffed GLP-1 telehealth startup demonstrates that low-end commoditization (prescribing-only, no behavioral support) is already occurring at massive scale. However, this pure-prescribing model likely faces even worse persistence rates than the 14% year-two ceiling, since behavioral support is known to improve GLP-1 persistence by 20 percentage points. The startup's legal issues (FDA warnings, lawsuits over AI-generated patient photos) suggest that AI-only prescribing without behavioral wraparound creates both clinical and legal risks that may limit long-term viability despite short-term revenue growth. diff --git a/inbox/queue/2026-04-28-llm-vs-human-glp1-coaching-commoditization-limits.md b/inbox/archive/health/2026-04-28-llm-vs-human-glp1-coaching-commoditization-limits.md similarity index 98% rename from inbox/queue/2026-04-28-llm-vs-human-glp1-coaching-commoditization-limits.md rename to inbox/archive/health/2026-04-28-llm-vs-human-glp1-coaching-commoditization-limits.md index ab1c661fc..e3954a1c5 100644 --- a/inbox/queue/2026-04-28-llm-vs-human-glp1-coaching-commoditization-limits.md +++ b/inbox/archive/health/2026-04-28-llm-vs-human-glp1-coaching-commoditization-limits.md @@ -7,11 +7,14 @@ date: 2025-01-01 domain: health secondary_domains: [ai-alignment] format: research -status: unprocessed +status: processed +processed_by: vida +processed_date: 2026-04-28 priority: medium tags: [LLM, AI-coaching, behavioral-support, GLP-1, commoditization, clinical-safety] intake_tier: research-task flagged_for_theseus: ["AI coaching safety: LLM behavioral health applications face same alignment concerns as clinical AI — formulaic responses, bias, privacy — at scale in consumer health context"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content